United Therapeutics Corp

NASDAQ:UTHRUnited States

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.

Contact Information

Headquarters

1000 SPRING STSILVER SPRING, MD, United States 20910

Phone

301-608-9292

Fax

301-608-9291

Executives

Chairman of the Board, Chief Executive Officer

Martine Rothblatt

President, Chief Operating Officer

Michael Benkowitz

Lead Independent Vice Chairman of the Board

Christopher Patusky

Chief Financial Officer, Treasurer

James Edgemond

Executive Vice President, General Counsel, Corporate Secretary

Paul Mahon